Vitreous fluorophotometry and changes in blood-retinal barrier permeability induced by bendazac lysine.
Vitreous fluorophotometry was used to investigate the effect of Bendazac lysine on the blood retinal barrier in 12 insulin-dependent diabetics with mild background retinopathy. The study was a randomized, double blind, cross-over trial, drug versus Placebo. Each treatment period was of 4 months. The vitreous penetration coefficient was reduced by 21% (95% c.i. 12, 30; p = 0.001) by treatment with respect to Placebo.
Nuzzi
G
G
Institute of Ophthalmology, University of Parma, Italy.
Venturini
I
I
De Gregorio
M
M
Arsenio
L
L
Maraini
G
G
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001813:Blood-Retinal Barrier / Q000187:drug effects* / Q000502:physiology; D002463:Cell Membrane Permeability; D018592:Cross-Over Studies; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000378:metabolism; D004311:Double-Blind Method; D005260:Female; D019793:Fluorescein; D005452:Fluoresceins / Q000008:administration & dosage; D005456:Fluorescent Dyes / Q000008:administration & dosage; D015590:Fluorophotometry; D005500:Follow-Up Studies; D006801:Humans; D007191:Indazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018401:Sample Size; D014822:Vitreous Body / Q000187:drug effects / Q000378:metabolism*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005452:Fluoresceins; D005456:Fluorescent Dyes; D007191:Indazoles; C036067:bendazac lysine; D019793:Fluorescein